Subscribe

Dr. Chovatiya, Director of the Center for Eczema and Itch in the Department of Dermatology at Northwestern University Feinberg School of Medicine, reviews clinical trial data evaluating the impact of oral and topical JAK inhibitors on itch in patients with atopic dermatitis (AD). His discussion focuses on the central role of pruritus in disease burden and how targeted therapies are reshaping symptom control.

Topics Covered

• The pathophysiology of itch in atopic dermatitis
• Clinical trial results assessing oral JAK inhibitors and itch reduction
• Evidence supporting topical JAK inhibitors for rapid itch improvement
• The importance of itch control in improving sleep, quality of life, and treatment adherence

Explore Related Resources

• Atopic Dermatitis and Itch Update 2024
• Improving Itch and Quality of Life in Patients with Atopic Dermatitis